Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorometholone + rebamipide is a combination ophthalmic formulation intended for topical use in the eye. Fluorometholone is a synthetic adrenocorticosteroid with potent anti-inflammatory properties, commonly used as an ophthalmic suspension to treat ocular inflammation. It acts primarily by inhibiting multiple inflammatory cytokines and mediators, thereby reducing swelling, redness, and discomfort in ocular tissues[1][3]. Rebamipide is a mucosal protective agent originally developed for gastrointestinal conditions but has also been formulated as an ophthalmic solution or suspension. Its mechanism involves stimulating prostaglandin production and enhancing mucin secretion on the ocular surface, which promotes epithelial healing and protects against damage from inflammation or dryness[2][5]. The combination aims to provide both anti-inflammatory effects (from fluorometholone) and enhanced epithelial protection/healing (from rebamipide), making it suitable for treating various inflammatory or injury-related eye conditions where both actions are beneficial[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorometholone + rebamipide.